Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Near-Infrared Fluorescence Imaging for Intraoperative Ureter Identification: A Systematic Review.

The Journal of surgical research·2026
Same author

Interpretation of Chemistry, Hematology and Coagulation Laboratory Results in Early-Phase Clinical Pharmacology Trials; a Retrospective Analysis Based on the Placebo Arm of Randomized-Controlled Trials.

Clinical and translational science·2026
Same author

Early immune responses to intradermal lipopolysaccharide in healthy volunteers: prednisolone's impact on TLR4-mediated inflammation.

Frontiers in immunology·2026
Same author

Digital diagnostics, biomarkers and therapeutics in an evolving healthcare system: From promise to practice.

British journal of clinical pharmacology·2026
Same author

Clinical Validation of Imaging Biomarkers in Mycosis Fungoides.

Experimental dermatology·2026
Same author

Standardizing clinical trials in near-infrared fluorescence imaging: a workflow and regulatory framework proposal.

Npj imaging·2026

Related Experiment Video

Updated: Jul 17, 2026

A Familiarization Protocol Facilitates the Participation of Children with ASD in Electrophysiological Research
08:42

A Familiarization Protocol Facilitates the Participation of Children with ASD in Electrophysiological Research

Published on: July 31, 2017

Stimulation programs for pediatric drug research--do children really benefit?

Isabelle Boots1, Rám N Sukhai, Richard H Klein

  • 1Department of Pediatrics, Leiden University Medical Center, Willem Alexander Kinder- en Jeugdcentrum, LUMC, Postbus 9600, 2300 RC Leiden, The Netherlands.

European Journal of Pediatrics
|January 18, 2007
PubMed
Summary

The Food and Drug Administration Modernization Act (FDAMA) stimulated pediatric drug studies, but these drugs are rarely used by children. Pediatric drug research priorities should align with patient needs, not market interests.

More Related Videos

Quantitative Assessment of Cortical Auditory-tactile Processing in Children with Disabilities
09:38

Quantitative Assessment of Cortical Auditory-tactile Processing in Children with Disabilities

Published on: January 29, 2014

Non-Invasive Modulation and Robotic Mapping of Motor Cortex in the Developing Brain
08:26

Non-Invasive Modulation and Robotic Mapping of Motor Cortex in the Developing Brain

Published on: July 1, 2019

Related Experiment Videos

Last Updated: Jul 17, 2026

A Familiarization Protocol Facilitates the Participation of Children with ASD in Electrophysiological Research
08:42

A Familiarization Protocol Facilitates the Participation of Children with ASD in Electrophysiological Research

Published on: July 31, 2017

Quantitative Assessment of Cortical Auditory-tactile Processing in Children with Disabilities
09:38

Quantitative Assessment of Cortical Auditory-tactile Processing in Children with Disabilities

Published on: January 29, 2014

Non-Invasive Modulation and Robotic Mapping of Motor Cortex in the Developing Brain
08:26

Non-Invasive Modulation and Robotic Mapping of Motor Cortex in the Developing Brain

Published on: July 1, 2019

Area of Science:

  • Pharmacology
  • Pediatric Medicine
  • Drug Development

Background:

  • Most pediatric prescriptions lack specific testing in children.
  • The Food and Drug Administration Modernization Act (FDAMA) incentivizes pediatric drug studies through patent extensions.
  • This legislation aims to improve evidence for safe and effective pediatric drug use.

Purpose of the Study:

  • To evaluate the effectiveness of FDAMA's pediatric exclusivity provision.
  • To assess if the provision increased pediatric drug research and improved drug use evidence.
  • To analyze drug utilization patterns in children for drugs granted exclusivity.

Main Methods:

  • Analysis of drugs granted pediatric exclusivity under FDAMA (July 1998-August 2006).
  • Review of pediatric study summaries and manufacturer labeling information.
  • Systematic literature search for pediatric drug utilization patterns.

Main Results:

  • 135 drug entities received pediatric exclusivity.
  • Common drug groups included antidepressants, ACE inhibitors, lipid-lowering agents, HIV antivirals, and NSAIDs.
  • Drug distribution mirrored adult market use, not actual pediatric utilization.
  • Despite increased studies, children infrequently used these exclusive drugs.

Conclusions:

  • FDAMA stimulated pediatric drug studies but did not align with children's actual drug needs.
  • Market considerations, rather than patient necessity, influenced drug research priorities.
  • Future pediatric drug research should prioritize patient-driven needs.